Ontology highlight
ABSTRACT:
INSTRUMENT(S): Orbitrap Fusion Lumos
ORGANISM(S): Homo Sapiens (human)
DISEASE(S): Pancreatic Cancer
SUBMITTER: Stephanie Wilhelm
LAB HEAD: Prof. Dr. Bernhard Kuster
PROVIDER: PXD018674 | Pride | 2022-05-12
REPOSITORIES: Pride
Items per page: 5 1 - 5 of 49 |
Lier Svenja S Sellmer Andreas A Orben Felix F Heinzlmeir Stephanie S Krauß Lukas L Schneeweis Christian C Hassan Zonera Z Schneider Carolin C Patricia Gloria Schäfer Arlett A Pongratz Herwig H Engleitner Thomas T Öllinger Rupert R Kuisl Anna A Bassermann Florian F Schlag Christoph C Kong Bo B Dove Stefan S Kuster Bernhard B Rad Roland R Reichert Maximilian M Wirth Matthias M Saur Dieter D Mahboobi Siavosh S Schneider Günter G
Bioorganic chemistry 20211120
Targeted protein degradation offers new opportunities to inactivate cancer drivers and has successfully entered the clinic. Ways to induce selective protein degradation include proteolysis targeting chimera (PROTAC) technology and immunomodulatory (IMiDs) / next-generation Cereblon (CRBN) E3 ligase modulating drugs (CELMoDs). Here, we aimed to develop a MYC PROTAC based on the MYC-MAX dimerization inhibitor 10058-F4 derivative 28RH and Thalidomide, called MDEG-541. We show that a subgroup of gas ...[more]